--- title: "Nurix Therapeutics 3Q 2026: Revenue $9.04M, EPS $(0.81) — 10-Q Summary" type: "News" locale: "en" url: "https://longbridge.com/en/news/292239293.md" description: "Nurix Therapeutics reported Q3 2026 results with revenue of $9.04M, down 35.6% YoY, and a net loss of $89.54M, widening from the prior year's $43.46M loss. Diluted EPS was $(0.81) versus $(0.52). The decline stemmed from reduced collaboration revenue as initial terms concluded. Pipeline progress includes Phase 2 for bexobrutideg and Phase 1 trials for zelebrudomide and NX-1607. New collaborations with Roche and ongoing partnerships with Gilead, Sanofi, and Pfizer continue to support discovery." datetime: "2026-07-09T20:21:02.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/292239293.md) - [en](https://longbridge.com/en/news/292239293.md) - [zh-HK](https://longbridge.com/zh-HK/news/292239293.md) generator: "portal-rs" --- # Nurix Therapeutics 3Q 2026: Revenue $9.04M, EPS $(0.81) — 10-Q Summary Nurix Therapeutics reported third-quarter results for the period ended May 31, 2026, with revenue of $9.04M and a net loss of $89.54M, or diluted loss per share of $(0.81), versus revenue of $14.06M, net loss of $43.46M and diluted loss per share of $(0.52) in the year‑ago quarter. **Financial Highlights** - Revenue was $9.04M for Q3 2026, compared with $14.06M in the year‑ago quarter; YoY change (35.6%). - Net income was a loss of $89.535M for Q3 2026, compared with a loss of $43.464M in the year‑ago quarter; loss widened by $46.071M YoY. - Diluted earnings per share was $(0.81) for Q3 2026, versus $(0.52) in the year‑ago quarter. **Business Highlights** - Pipeline progress: continued Phase 2 for bexobrutideg and Phase 1 trials for zelebrudomide and NX‑1607, with enrollment and dose escalation advancing. - Collaborations and licensing: new Roche collaboration for bexobrutideg and ongoing partnerships with Gilead, Sanofi and Pfizer continue to support discovery and provide non‑dilutive funding. - Revenue mix shift: collaboration revenue declined as initial research terms concluded and license milestone timing reduced 2026 license revenue. - DEL‑AI platform: ongoing use of the proprietary DEL‑AI discovery platform supports multiple partnered programs and has generated $489M in non‑dilutive proceeds to date. - Operational scale‑up: increased spending on clinical trials, CMOs and contract research, along with higher personnel and stock‑based compensation to support growth. Original SEC Filing: Nurix Therapeutics, Inc. \[ NRIX \] - 10-Q - Jul. 09, 2026 **Disclaimer** This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC. ### Related Stocks - [NRIX.US](https://longbridge.com/en/quote/NRIX.US.md) - [PFE.US](https://longbridge.com/en/quote/PFE.US.md) - [GILD.US](https://longbridge.com/en/quote/GILD.US.md) - [GIS.DE](https://longbridge.com/en/quote/GIS.DE.md) - [RHHBY.US](https://longbridge.com/en/quote/RHHBY.US.md) - [SNY.US](https://longbridge.com/en/quote/SNY.US.md) - [RHHVF.US](https://longbridge.com/en/quote/RHHVF.US.md) - [SNYNF.US](https://longbridge.com/en/quote/SNYNF.US.md) ## Related News & Research - [NEOS Investment Management LLC Has $120.08 Million Position in Gilead Sciences, Inc. $GILD](https://longbridge.com/en/news/298019220.md) - [Simcere Zaiming licenses SIM0660 to Roche in deal worth up to $1.53 billion](https://longbridge.com/en/news/297652647.md) - [DualityBio signs Genentech ADC collaboration, secures USD 45 million upfront, over USD 1 billion milestones](https://longbridge.com/en/news/297612881.md) - [New HIV and Breast Cancer Wins Might Change The Case For Investing In Gilead Sciences (GILD)](https://longbridge.com/en/news/297483843.md) - [Medicus Pharma signs co-development, licensing deal with Pfizer for CD228V antibody-drug conjugate](https://longbridge.com/en/news/297910433.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**